Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2025—Diasorin has received FDA 510(k) clearance for the Simplexa COVID-19/Flu A/B and RSV Direct kit, a sample-to-answer test for the detection of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus directly from nasopharyngeal and nasal swab specimens. The kit runs on the Liaison MDX system and provides differential detection in about 45 minutes.
December 2025—The Journal of Clinical Microbiology has published an article describing ARUP Laboratories’ validation of a deep convolutional neural network to detect parasites in concentrated wet mounts of stool.
December 2025—Smart In Media has released version 3.2 of its PathoZoom Scan and LiveView. The new version includes enhancements to workflow, image transmission, and LIS integration.
December 2025—Qiagen has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research, for $225 million. The acquisition will expand Qiagen’s Sample technologies portfolio into the single-cell sequencing market with highly scalable chemistry designed to power research involving millions of billions of cells, according to a press release from Qiagen. Parse’s scalable chemistry is also expected to accelerate growth in Qiagen’s digital insights bioinformatics business.
December 2025—The FDA has approved QuidelOrtho Corp.’s Micro Typing Systems DAT card, a gel-based solution for direct antiglobulin testing, and the Ortho Vision platform, an automated blood testing system.
December 2025—The Food and Drug Administration has granted expanded clearance for use of the FecalSwab sample type across all Qiagen QIAstat-Dx gastrointestinal panels, enabling full pathogen detection, including of Shiga toxin–producing E. coli and enteropathogenic E. coli. STEC and EPEC can now be reported when testing by FecalSwab collected from stool samples with the QIAstat-Dx Gastrointestinal Panel 2, including detection of clinically relevant STEC subtypes such as stx2f. STEC can now also be reported for the QIAstat-Dx GI Panel 2 Mini B and QIAstat-Dx GI Panel 2 Mini B&V.
December 2025—Proscia is introducing virtual staining, powered by Pictor Labs, to its Concentriq software platform to help laboratories reduce the costs associated with traditional chemical methods and drive efficiency in high-throughput workflows. Virtual staining uses AI models to replicate the effects of stains on tissue images. These models can generate a whole slide virtually stained image from label-free inputs in a few minutes. The company will integrate a menu of H&E, immunohistochemical, and special stains into Concentriq.
December 2025—GSI Group Holdings has acquired GenesisBPS, a designer and manufacturer of specialized benchtop blood processing equipment and laboratory consumables. GSI Group provides a wide range of laboratory single-use products, benchtop instruments, and related accessories and has locations across the U.S., Europe, and Asia. GenesisBPS joins GSI Group brands Globe Scientific, AmScope, Euromex, and Physix, among others.
November 2025—The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for treating extensive-stage small cell lung cancer after platinum-based chemotherapy.
November 2025—Streck added the Accellix automated cell phenotyping platform to its CD-Chex Plus (RUO) control.
